

Tomáš Ā Ā tulc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6733931/publications.pdf>

Version: 2024-02-01

29
papers

799
citations

840119

11
h-index

552369

26
g-index

35
all docs

35
docs citations

35
times ranked

1149
citing authors

#	ARTICLE	IF	CITATIONS
1	A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. <i>Archives of Medical Science</i> , 2017, 4, 705-710.	0.4	9
2	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. <i>International Journal of Cardiology</i> , 2016, 225, 184-196.	0.8	155
3	Statin Intolerance: the Clinician's Perspective. <i>Current Atherosclerosis Reports</i> , 2015, 17, 69.	2.0	43
4	Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?. <i>Current Pharmaceutical Design</i> , 2015, 21, 1180-1184.	0.9	1
5	Ivabradine in Stable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2014, 371, 2435-2435.	13.9	16
6	Ivabradine, Coronary Heart Disease, and Heart Failure: Time for Reappraisal. <i>Current Atherosclerosis Reports</i> , 2014, 16, 463.	2.0	2
7	Statins, Glycemia, and Diabetes Mellitus: Another Point of View. <i>Current Atherosclerosis Reports</i> , 2014, 16, 458.	2.0	4
8	The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus. <i>Neuroendocrinology Letters</i> , 2012, 33 Suppl 2, 73-7.	0.2	1
9	Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects?. <i>Diabetes Research and Clinical Practice</i> , 2010, 88, 125-131.	1.1	51
10	Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?. <i>Medical Hypotheses</i> , 2008, 70, 199-200.	0.8	2
11	IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY. <i>Atherosclerosis Supplements</i> , 2008, 9, 40.	1.2	2
12	APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 773-7.	1.4	12
13	Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?. <i>Medical Science Monitor</i> , 2008, 14, RA45-7.	0.5	3
14	Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. <i>Nutrition Research</i> , 2007, 27, 181-185.	1.3	1
15	PO9-212 EFFECT OF ROSIGLITAZONE ON LEUKOCYTE EXPRESSION OF PROINFLAMMATORY AND PROTHROMBOTIC MOLECULES IN PATIENTS WITH TYPE 2 DIABETES. <i>Atherosclerosis Supplements</i> , 2007, 8, 69.	1.2	0
16	PO17-487 ADEQUATELY TREATED TYPE 2 DIABETES IS ASSOCIATED WITH LOWER WALL SHEAR RATE OF THE COMMON CAROTID ARTERY. <i>Atherosclerosis Supplements</i> , 2007, 8, 136.	1.2	1
17	We-P11:117 Rosiglitazone improves quality of lipoproteins in patients with type 2 diabetes. <i>Atherosclerosis Supplements</i> , 2006, 7, 371.	1.2	0
18	Is it safe to combine PPAR agonists? A lesson from muraglitazar. <i>Medical Hypotheses</i> , 2006, 67, 669.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2005, 183, 367-368.	0.4	7
20	W15-P-006 Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. <i>Atherosclerosis Supplements</i> , 2005, 6, 98.	1.2	0
21	Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. <i>European Journal of Pharmacology</i> , 2004, 493, 183-189.	1.7	35
22	Repeatability of noninvasive surrogates of endothelial function. <i>American Journal of Cardiology</i> , 2004, 94, 693-696.	0.7	30
23	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. <i>Atherosclerosis</i> , 2003, 166, 195-196.	0.4	8
24	Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2003, 166, 197-198.	0.4	8
25	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. <i>American Heart Journal</i> , 2003, 146, 110A-115A.	1.2	22
26	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. <i>American Heart Journal</i> , 2003, 146, 1060-1063.	1.2	26
27	Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. <i>Nutrition</i> , 2001, 17, 721-723.	1.1	57
28	Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. <i>Journal of Clinical Investigation</i> , 2000, 106, 1263-1270.	3.9	295
29	Immunocytochemical detection of estrogen receptors in bone cells using flow cytometry. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1997, 1356, 95-100.	1.9	7